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Due to its exposure to high concentrations of xenobiotics, the kidney proximal tubule
is a primary site of nephrotoxicity and resulting attrition in the drug development
pipeline. Current pre-clinical methods using 2D cell cultures and animal models are
unable to fully recapitulate clinical drug responses due to limited in vitro functional
lifespan, or species-specific differences. Using Organovo’s proprietary 3D bioprinting
platform, we have developed a fully cellular human in vitro model of the proximal tubule
interstitial interface comprising renal fibroblasts, endothelial cells, and primary human
renal proximal tubule epithelial cells to enable more accurate prediction of tissue-level
clinical outcomes. Histological characterization demonstrated formation of extensive
microvascular networks supported by endogenous extracellular matrix deposition. The
epithelial cells of the 3D proximal tubule tissues demonstrated tight junction formation
and expression of renal uptake and efflux transporters; the polarized localization and
function of P-gp and SGLT2 were confirmed. Treatment of 3D proximal tubule tissues
with the nephrotoxin cisplatin induced loss of tissue viability and epithelial cells in a
dose-dependent fashion, and cimetidine rescued these effects, confirming the role of
the OCT2 transporter in cisplatin-induced nephrotoxicity. The tissues also demonstrated
a fibrotic response to TGFβ as assessed by an increase in gene expression associated
with human fibrosis and histological verification of excess extracellular matrix deposition.
Together, these results suggest that the bioprinted 3D proximal tubule model can serve as
a test bed for the mechanistic assessment of human nephrotoxicity and the development
of pathogenic states involving epithelial-interstitial interactions, making them an important
adjunct to animal studies.
Keywords: proximal tubule, 3D model, nephrotoxicity, drug safety, renal transporters
Abbreviations: 3D, three-dimensional; ACE, angiotensin-converting enzyme; AGT, angiotensinogen; AGTR1, angiotensin
receptor type I; AKI, acute kidney injury; DPBS, Dulbecco’s phosphate buffered saline; ECM, extracellular matrix; H&E,
hematoxylin and eosin; HUVEC, human umbilical vein endothelial cell; LDH, lactate dehydrogenase; OCT, organic cation
transporter; Papp, passive permeability; PCNA, proliferating cell nuclear antigen; PT, proximal tubule; R123, rhodamine
123; RAS, renin-angiotensin system; RFU, relative fluorescence units; RPTEC, renal proximal tubule epithelial cell; TEER,
trans-epithelial electrical resistance.
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INTRODUCTION
The kidneys play a central role in the metabolism and
elimination of a variety of drugs, with the proximal tubule (PT)
being exposed to high concentrations of reactive hydrophilic
metabolites at both the luminal surface following filtration of
plasma at the glomerulus, as well as the basolateral surface
following absorption from the peritubular capillaries. Due to
the action of renal xenobiotic transporters expressed in the
PT epithelium, pharmaceutical compounds can accumulate
and become concentrated in the PT and may then undergo
further metabolism by cytochrome P450 enzymes and UDP-
glucuronyltransferases (Lohr et al., 1998). While this serves
a role in detoxifying these compounds to generate more
hydrophilic molecules that are secreted into the urine, highly
toxic intermediate metabolites can accumulate and cause damage
to the tubular epithelium and surrounding cells (Choudhury and
Ahmed, 2006). As such, a major challenge in bringing new drugs
tomarket is the risk of nephrotoxicity, which is often detected late
in drug development; attrition due to nephrotoxicity accounts
for 2% of preclinical drug attrition but 19% of attrition during
more costly phase 3 clinical trials (Redfern, 2010). Post-approval,
drug-induced nephrotoxicity accounts for as much as 18–27%
of cases of acute kidney injury (AKI) (Loghman-Adham et al.,
2012), with up to 36% of these injuries related to commonly
used antibiotics such as aminoglycosides (Kleinknecht et al.,
1987). While many of these AKI cases are reversible, some drugs
can induce chronic renal injury resulting in tubular necrosis,
tubulointerstitial inflammation, and fibrosis (Kleinknecht et al.,
1987; Choudhury and Ahmed, 2006). Currently, diagnosis of
AKI or renal failure relies on elevated creatinine or blood
urea nitrogen levels, which do not become reliably clinically
significant until the injury is severe (Rahman et al., 2012).
The lasting effects of AKI are significant, with 13% of patients
requiring continued dialysis and 41% of patients requiring kidney
transplant due to renal insufficiency (Vaidya et al., 2008). Better
predictive tools for identifying nephrotoxic drugs during the drug
development process would therefore reduce the costs associated
both with bringing a new drug to market and in treating the
downstream effects of AKI, as well as improving patients’ lives.
Currently, widely used screening tools for nephrotoxic
compounds consist primarily of panels of human and animal
renal proximal tubule epithelial cells (RPTEC) or small animal
models. However, these systems often fail to accurately predict
organ-specific toxicity, either as a result of species-specific
differences, or the inability to recapitulate relevant aspects
of kidney physiology, including toxicity following xenobiotic
transport and biotransformation (Lin and Will, 2012). While
freshly isolated primary human RPTEC obviate differences in
species specificity, the cells rapidly dedifferentiate and senesce
when cultured in isolation, losing expression of key transporters
and metabolic enzymes (Hallman et al., 2008; Wieser et al.,
2008; Vesey et al., 2009). In the human kidney, the RPTEC
exist in close connection with the renal interstitium, defined
as the space between the cortical tubules comprising cells,
extracellular matrix, proteoglycans, glycoproteins, and interstitial
fluid (Lemley and Kriz, 1991). The cell types found in the cortical
interstitium include fibroblast-like cells and immune cells,
which are interspersed with the microvasculature of peritubular
capillaries (Brenner, 2008). These supporting cell types may play
a key role in maintaining the continued function of RPTEC,
as co-culture of primary RPTEC with endothelial cells results
in a robust paracrine signaling network that improves RPTEC
proliferation and differentiation (Tasnim and Zink, 2012). Thus,
placing primary RPTEC together with supporting interstitial cells
in a more native, three-dimensional (3D) architecture may aid
in maintaining their function over time, as well as allowing for
assessment of additional types of kidney injury that are difficult to
model using epithelial cells alone, such as fibrosis (Subramanian
et al., 2010).
One of the primary aims of tissue engineering is to use living
cells and biomaterials to generate 3D tissues that recapitulate
key aspects of the architecture and function of a native tissue
or organ. With proper in vitro or in vivo conditioning, the cells
within these structures can respond to soluble and mechanical
cues by establishing cell-cell and cell-matrix interactions that
mimic some aspects of native tissue (Griffith et al., 2014). It is
well established that cells cultured in 3D configurations, such
as spheroids or collagen gels, perform differently in functional
assays than 2D cultures, and the physiologic responses of cells in
3D more closely approximate responses observed in vivo (Godoy
et al., 2013). One such means for fabricating these 3D structures
is bioprinting. In this approach, bioinks composed of cellular
material are extruded in reproducible, geometrically-defined
patterns created by the investigator (Ozbolat and Hospodiuk,
2016). The bioink is composed of self-assembling multicellular
aggregates that adhere to one another following deposition,
leading to formation of complex, patterned tissues (Jakab et al.,
2008, 2010). Combining the use of self-assembling multicellular
aggregates with computer-controlled bioprinting allows the
creation of highly reproducible, scaffold-free tissues that form
and mature in the absence of exogenous extracellular matrix
that can interfere with direct cell-cell contacts (Norotte et al.,
2009). In the current study, Organovo’s proprietary bioprinting
technology was leveraged to design and create layered tissue
models of the human PT that incorporate key interstitial cell
types supporting RPTEC to facilitate both cell-cell interactions
and paracrine signaling between renal fibroblasts, endothelial
cells, and epithelial cells. The resulting engineered tissues were
then characterized in three main areas: validation of key
physiologic aspects of the native proximal tubule, confirmation of
the ability to detect nephrotoxicity using the well-characterized
nephrotoxin cisplatin, and demonstration of the utility of
the model in evaluating renal fibrosis. The tissues supported
physiologically relevant epithelial morphology and function for
at least 30 days in culture, and were effectively used to model
the role of the organic cation transporter OCT2 in nephrotoxic
responses to cisplatin using a combination of biochemical,
transcriptional, and histological endpoints. In addition, the
tissues demonstrated a fibrotic response to the cytokine TGFβ,
a phenotype that is not possible in isolated epithelial cell culture
systems. Based on these initial validation studies, this system
may be useful in predicting nephrotoxicity of pharmaceutical
compounds earlier in the drug development process.
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MATERIALS AND METHODS
Cell Culture
Human umbilical vein endothelial cells (HUVEC) were
purchased from BD Biosciences (Franklin Lakes, NJ) and
cultured in EGM-2 media with EBM-2 supplements without
gentamycin or amphotericin B (Lonza, Basel, Switzerland).
Adult renal fibroblasts were purchased from DV Biologics
(Yorba Linda, CA) and grown in Fibroblast Cellutions Medium
with Fibroblast Cellutions supplement (DV Biologics, Yorba
Linda, CA). Primary human RPTEC were purchased from four
different commercial vendors (Lonza lot number 0000385391),
Sciencell (lot number 11022; Carlsbad, CA), Zen-Bio (lot
number RPCT082011; Research Triangle Park, NC), Lifeline Cell
Technology (lot number 02685; Frederick, MD) and cultured
according to the manufacturer’s instructions.
RPTEC Isolation and Culture
All kidneys were ethically sourced through the National Disease
Research Interchange (Philadelphia, PA). RPTEC cells [available
from Samsara Sciences (San Diego, CA)] were isolated using
standard methodologies as previously described (Vesey et al.,
2009). In brief, upon receipt, kidneys were aseptically unpacked
and cleaned to remove any remaining fat pads, ureters, blood
vessels or other tissue. Sections of cortical tissue were minced,
digested with collagenase, and the collected cells were enriched
for epithelium by centrifugation across an iodixanol gradient
(Sigma-Aldrich, St. Louis, MO). RPTECs were cultured in
GBGTM Epithelial Media (Samsara Sciences, San Diego, CA).
3D Bioprinting and Tissue Culture
3D PT ExViveTM Human Kidney Tissue was fabricated as
described (Nguyen et al., 2016b). Briefly, cultured renal
fibroblasts and HUVEC were combined in a 50:50 ratio and
resuspended in thermo-responsive NovoGel R© Bio-Ink, and then
bioprinted onto 0.4 µm Transwell clear polyester membrane
inserts in a 24-well plate (Corning Costar, Corning, NY) using
a NovoGen Bioprinter R© Instrument (Organovo Inc., San Diego,
CA) with previously established protocols (Nguyen et al., 2016a).
Following bioprinting, the tissues were cultured in 3D PT Tissue
media comprising EGM-2 media with EBM-2 supplements
without gentamycin and GBGTM Epithelial Media (Samsara
Sciences, San Diego, CA). On culture day 3, primary RPTEC
cells were added to the tissues in a suspension of 1.25 × 106
cells/ml in RPTEC media. Tissues were then maintained for up
to 30 days in 3D PT Tissue media described above and 2.5%
final v/v FBS, with media exchanges every other day. For toxicity
and fibrosis studies, tissues were dosed daily with cisplatin and
TGFβ in culture media supplemented with a final concentration
of 2.5% FBS v/v in both the apical and basolateral compartments
beginning at day 14 of culture.
Metabolic Activity and Viability Assays
Assessment of metabolic activity as a surrogate for tissue viability
and health was performed by alamarBlueTM Assay according
to the manufacturer’s protocol (Thermo Fisher, Carlsbad, CA).
Briefly, tissues were washed twice with Dulbecco’s phosphate
buffered saline (DPBS), and RPTEC media supplemented with
10% v/v alamarBlue reagent was added to each tissue. All tissues
were incubated for 2 h at 37◦C with 95% relative humidity and
5% CO2. After incubation, the alamarBlue solution was removed
and fluorescence was measured on a BMG Labtech POLARstar
Omega plate reader (Cary, NC) with an excitation filter of 560
nm and an emission filter of 590 nm. Graphed data represent
the percent relative fluorescence units (RFU) compared to blank
for metabolic activity over time, or the percent RFU compared to
vehicle control for toxicity studies.
Lactate dehydrogenase (LDH) activity assay was performed
according to the manufacturer’s protocol (Abcam, Cambridge,
MA). Conditioned media was collected from 3D PT tissues
and further diluted in fresh media to ensure that the LDH
activity of the sample was within the linear range of the assay.
Samples were measured on a microplate reader (BMG Labtech,
Cary, NC). LDH activity was determined by standard curve
integration of absorbance normalized for volume and duration
using GraphPad Prism software (GraphPad, San Diego, CA).
Data shown represent the fold change in LDH activity relative
to vehicle control for each day of sampling.
GGT Assay
GGT activity was measured according to the manufacturer’s
protocol (Sigma Aldrich, St. Louis, MO). Tissues were washed
twice with DPBS and lysed in GGT assay buffer in a Precellys
lysis tube (Precellys, Rockville, MD). Lysate was assessed for
GGT activity by comparison to a standard curve integration of
absorbance normalized for volume and duration of incubation
period at 37◦C using GraphPad Prism software (GraphPad, San
Diego, CA). Data shown represent the average GGT activity
in mIU/ml for analysis of GGT function over time, or percent
relative to vehicle for toxicity studies.
Trans-Epithelial Electrical Resistance
(TEER) and Permeability Measurements
To measure TEER, individual 3D PT tissues cultured for 21
d were removed from the Transwell insert and loaded into
an Ussing chamber (Physiologic Instruments, San Diego, CA).
Studies were run essentially as previously described (Clarke,
2009). Tissues were bathed in Krebs bicarbonate ringer solution
with glucose (115mMNaCl, 2.4 mMK2HPO4, 0.4 mMKH2PO4,
1.2 mM CaCl2 dihydrate, 1.2 mM MgCl2 hexahydrate, 25 mM
NaHCO−3 , 10 mM glucose; all reagents from Sigma-Aldrich, St.
Louis, MO) and buffer was continuously bubbled with carbogen
gas (95% O2/5% CO2). After correcting the electrode offset
potential and liquid resistance, resistance across the tissues was
measured continuously for 1 h.
For apparent permeability (Papp) measurements, tissues or
empty Transwells were washed with DPBS three times and
equilibrated to assay buffer (DPBS with 10 mM HEPES pH
7.4) for 10 min at 37◦C. Tissues were then dosed with 250
µM Lucifer yellow (Thermo Fisher, Carlsbad, CA) to either the
apical or basolateral compartment and fresh assay buffer in the
opposing receiver) compartment. Following incubation for 1 h at
37◦C, samples were taken from both the apical and basolateral
compartments. Fluorescence in each sample was measured on
a BMG plate reader with an excitation filter of 490 nm and
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an emission filter of 540 nm (BMG Labtech, Cary, NC) and
normalized to a standard curve for quantification. Papp was
calculated with equation 1 and 2, where V represents the volume
of Lucifer yellow solution, T is the duration of the incubation, D0
is the concentration of Lucifer yellow applied to the cells, and A
is the growth area of the Transwell insert. Apparent permeability
was calculated for each direction (A→B and B→A) and the ratio
of these values was then calculated by using Equation (3).
PappA→B = (
V
A
x D0)) ∗ (1D/1T) (1)
PappB→A = (
V
A
x D0)) ∗ (1D/1T) (2)
Eﬄux ratio =
PappB→ A
Papp A→ B
(3)
ELISA Assay for Angiotensin-Converting
Enzyme (ACE) and Angiotensin II
ACE protein levels in both tissue lysates and conditioned media
were detected by ELISA using the manufacturer’s instructions
(Abcam, Cambridge, MA). Plates were read at 450 nM (BMG
Labtech, Cary, NC) within 30 min of addition of the stop
solution. Concentrations of the test samples were determined
by comparison to the standard curve using GraphPad Prism
software (GraphPad, San Diego, CA).
To evaluate ACE enzyme function, 3D PT tissues were
treated for 24 h with 5 ng/ml human angiotensin I (Abcam,
Cambridge, MA) and angiotensin II was then detected using
a competitive ELISA kit from Sigma per the manufacturer’s
instructions (Sigma-Aldrich, St. Louis, MO). Plates were read at
450 nM within 30 min of addition of the stop solution (BMG
Labtech, Cary, NC). The concentration of angiotensin II in the
test samples was determined by comparison to the standard curve
using GraphPad Prism software (GraphPad, San Diego, CA).
Histology
3D PT were fixed overnight in 2% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA). Tissues were oriented for
transverse sectioning by pre-embedding in HistoGel (Thermo
Fisher, Carlsbad, CA) and were then dehydrated and infiltrated
with paraffin by automated processing on a TissueTek VIP
tissue processing system (Sakura Finetek USA, Torrance,
CA). Tissues were sectioned at 5 µM on a Jung Histocut
microtome (Leica Biosystems, Buffalo Grove, IL). Hematoxylin
and eosin (H&E) or Gomori’s trichrome (TCM) stains were
generated using a Leica Autostainer XL (Leica Biosystems,
Buffalo Grove, IL) according to manufacturer’s instructions.
Immunohistochemistry was performed as previously described
(King et al., 2013) using the primary antibodies in Table 1.
Following overnight incubation with primary antibodies at 4◦C,
sections were stained with AlexaFluor-conjugated secondary
antibodies (Thermo Fisher, Carlsbad, CA) at a 1:200 dilution.
For P-gp and SGLT2 detection, tyramide signal amplification
was performed according to the manufacturer’s instructions
(Thermo Fisher, Carlsbad, CA). Slides were counterstained and
mounted with FluoroGel II with DAPI (Electron Microscopy
Sciences, Hatfield, PA). H&E and TCM images were acquired
TABLE 1 | List of antibodies used.
Dilution Vendor
Rabbit α-CD31 1:100 Abcam (Cambridge, MA)
Mouse α-TE7 1:500 EMD Millipore (Temecula, CA)
Mouse α-collagen IV 1:100 Abcam
Rabbit α-E-cadherin 1:50 Abcam
Rabbit α-Pgp 1:500 Abcam
Rabbit α-SGLT2 1:250 Abcam
Rabbit α-Na+K+ATPase 1:100 Abcam
Mouse α-cytokeratin 18 1:500 Abcam
Rabbit α-PCNA 1:1000 Cell signaling (Danvers, MA)
on a Zeiss Axioskop with Zeiss Zen software (Zeiss Microscopy,
Thornwood, NY). Immunofluorescent images were acquired on
a Zeiss AxioImager A2 with Zeiss Zen software.
Quantification of Collagen by Sirius
Red/Fast Green Staining
Formalin-fixed, paraffin-embedded 3D PT tissues dosed with
vehicle or TGFβ were sectioned at 20 µM and dewaxed and
rehydrated as described above. Tissues sections were stained
using a Sirius Red and Fast Green staining kit and washed
extensively according to manufacturer’s protocol (Chondrex,
Redmond, WA). Following washing, dye was extracted with Dye
Extraction Buffer (Chondrex), and measured on a microplate
reader (BMG Labtech). Collagenous proteins stained with Sirius
Red were detected at 540 nm and non-collagenous proteins
stained with Fast Green were detected at 605 nm. The amount
of collagen normalized to total protein content was calculated for
4 individual tissue sections from each of 3 tissues. Data shown
represents the fold change of normalized collagen content relative
to the vehicle control.RNA Isolation and Quantitative RT-PCR.
RNA Isolation and Quantitative RT-PCR
RNA extraction from 3D PT tissues was performed using
the Zymo Direct-zol RNA kit according to the manufacturer’s
instructions (Zymo Research, Irvine, CA). RNA was quantified
by spectrophotometry using a NanoDrop 2000 (Thermo Fisher,
Carlsbad, CA) and converted to cDNA using SuperScript III
First-Strand Synthesis SuperMix according to the manufacturer’s
instructions (Thermo Fisher, Carlsbad, CA). Amplification
reactions were performed with 200 ng of cDNA using TaqMan
Gene Expression Array Cards (Thermo Fisher, Carlsbad, CA)
with GAPDH amplification as an endogenous housekeeping
control gene. TaqMan probe/primer sets are described in
Table 2. Amplification was detected on a ViiA7 real-time PCR
system (Thermo Fisher, Carlsbad, CA). Duplicate samples from
individual tissues were assessed. Relative quantitation (RQ)
values for the gene of interest compared to GAPDH were
calculated using the formula RQ= (2−1Ct)∗10000. RQ values for
each sample were normalized for KRT18 by dividing the RQ for
the gene of interest compared to GAPDH by the RQ for KRT18
compared to GAPDH. The fold change was then calculated by
dividing the KRT18-normalized RQ at the experimental day by
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TABLE 2 | Taqman probe/primer sets used.
Gene Gene symbol Assay ID
ACE ACE Hs00174179_m1
AGT AGT Hs01586213_m1
Renin REN Hs00982555_m1
MDR1 (P-gp) ABCB1 Hs00184500_m1
BCRP ABCG2 Hs01053790_m1
AQP1 AQP1 Hs01028916_m1
Cubilin CUBN Hs00153607_m1
Megalin LRP2 Hs00189742_m1
OCT2 SLC22A2 Hs01010723_m1
OAT1 SLC22A6 Hs00537914_m1
OAT3 SLC22A8 Hs00188599_m1
MATE1 SLC47A1 Hs00217320_m1
MATE2K SLC47A2 Hs00945650_m1
SGLT2 SLC5A2 Hs00894642_m1
NAPT2C SLC34A3 Hs02341449_m1
NHE3 SLC9A3 Hs00903842_m1
COL1A1 COL1A1 Hs00164004_m1
CTGF CTGF Hs01026927_g1
PDGFRB PDGFRB Hs01019589_m1
FAP FAP Hs00990806_m1
the KRT18-normalized RQ for day 3 (or day 12 for SGLT2,
NHE3, and NAPT2C).
LC-MS/MS-Based Detection of Renal
Transporters
The ProteoExtract R© Native Membrane Protein Extraction Kit
was purchased from Calbiochem/MerckMillipore (Darmstadt,
Germany). The protein quantification bicinchoninic acid
(BCA) assay kit, sequencing-grade trypsin, iodoacetamide
(IAA), and dithiothreitol (DTT) were purchased from Pierce
Biotechnology (Rockford, IL). Chloroform, high-performance
liquid chromatography (HPLC)-grade acetonitrile/methanol,
and formic acid were purchased from Fischer Scientific (Fair
Lawn, NJ). Ammonium bicarbonate (98% purity) and sodium
deoxycholate (DOC, 98% purity) were obtained from Thermo
Fisher Scientific (Rockford, IL) and MP Biomedicals (Santa Ana,
CA), respectively.
3D PT tissues cultured for 21 days or pieces of normal
human kidney cortex were subjected to targeted proteomic
analysis for OAT1, OAT3, OCT2, and P-gp and human serum
albumin (HSA, internal standard). Total membrane was isolated
from the 3D PT tissues and normal human kidney cortex
using a protocol previously described (Prasad et al., 2014).
Quantification of the total protein concentration was determined
using a BCA assay and the final membrane fraction was diluted
to a working concentration of 0.5 µg membrane protein/µL.
Total membrane proteins were spiked with 20 uL of HSA (10
ug/mL) and subsequently reduced, denatured, alkylated and
digested using a previously reported protocol (Wang et al.,
2015). All samples were digested and the surrogate peptides
generated by trypsin digestion were monitored by LC-MS/MS
as described below. Peptides unique for each transporter were
selected based on in silico selection criteria (Kamiie et al., 2008;
Prasad and Unadkat, 2014). Surrogate peptides were monitored
using an API 3000 triple quadrupole tandem mass spectrometer
(Applied Biosystems/MDS Sciex, Foster City, CA) coupled to
an Agilent R© 1290 Infiniti IITM UPLC system (Agilent, Palo
Alto, CA).
Briefly, a UPLC column (Acquity UPLC R© HSS T3 1.8 µm,
2.1 × 100 mm, Waters), with a Security Guard column (C18,
4 × 2.0 mm) from Phenomenex (Torrance, CA), was eluted (0.3
mL/min) with a gradient mobile phase consisting of water and
acetonitrile (with 0.1% formic acid). Peptides were eluted with a
gradient of 3–60% acetonitrile over 23 min, followed by a return
to starting conditions for 4 min to re-equilibrate the system. The
injection volume was 5 µL (∼2.5 µg of total protein). The mass
spectrometer was set up to run a multiplexed MRM experiment
for the optimal peptides. The MRM transitions for the analyte
peptides were monitored using LC-MS/MS parameters in ESI
positive ionization mode. The total peak area of the selected
peptide was normalized to HSA from the same sample and
were determined using Skyline (MacCoss Lab, University of
Washington).
Glucose Uptake Colorimetric Assay
Glucose uptake in 3D PT tissues was detected and quantified
according to the manufacturer’s protocol (Abcam, Cambridge,
MA). Insulin-Transferrin-Selenium (Gibco, Carlsbad, CA) was
used to stimulate glucose uptake and canagliflozin (Santa Cruz
Biotech, Dallas, TX) was used to inhibit SGLT2 function.
Tissues were starved overnight in DPBS/HEPES, pH 7.4 prior
to assay. Tissues were then pretreated with 1X insulin or 500
µM canagliflozin for 20 min, followed by addition of 1 mM
2-deoxyglucose. Tissues were washed extensively with PBS and
lysed in extraction buffer in Precellys lysis tubes (Precellys,
Rockville, MD). 2-deoxyglucose uptake was measured at OD412
nm on a microplate reader (BMG Labtech, Cary, NC) and results
were graphed as fold change relative to control using GraphPad
Prism Software (GraphPad, San Diego).
Vectorial Transport of Rhodamine 123
3D PT tissues were washed with DPBS three times and
equilibrated to assay buffer (DPBS supplemented with 10
mM HEPES, pH 7.4) for 10 min at 37◦C. Both apical and
basolateral sides of tissues were then pre-incubated for 20 min
at 37◦C in assay buffer in the presence or absence of 5 µM
zosuquidar (Sigma Aldrich, St. Louis, MO). Following pre-
treatment, tissues were dosed on the basolateral side with 1
µM rhodamine 123 (Molecular Probes, Eugene, OR) with or
without 5 µM zosuquidar for 2h at 37◦C. After incubation, the
tissues were washed with cold assay buffer, fixed with 2% PFA,
and cryosectioned. Images were captured at the same exposure
time across all conditions. Fluorescence intensity, corrected for
background and relative area, was calculated in Image J (National
Institutes of Health, Bethesda, MD) and graphed as fold change
relative to control using GraphPad Prism Software (GraphPad,
San Diego).
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Statistical Analysis
Statistics were calculated using GraphPad Prism software (La
Jolla, CA). Data shown is themean± SEM. Statistical significance
(P < 0.05) was calculated by t-test with Dunnet’s post-test,
one-way ANOVA, or two-way ANOVA as appropriate.
RESULTS
Development and Characterization of a 3D
Model of the Tubulointerstitial Interface of
the Human PT
Cultured primary human RPTECs have a finite lifespan in
culture before undergoing epithelial-to-mesenchymal transition
or senescence, with accompanying loss of morphology and
function (Wieser et al., 2008). Abundant evidence supports the
notion that an appropriate microenvironment, including 3D
architecture and supporting cell types, can help maintain and
support the continued health and function of polarized epithelia
(Kunz-Schughart et al., 2006; Bryant and Mostov, 2008; Nagle
et al., 2011; Li et al., 2014). To develop a 3D human system
for studying nephrotoxicity, the Organovo NovoGen Bioprinter
system was used to create a model of the PT tubulointerstitial
interface (ExVive tissues). As shown in the schematic of
Figure 1A, tissues were designed with a basal multicellular
interstitial layer composed of primary human renal fibroblasts
and HUVEC, and an apical monolayer of polarized primary
human RPTEC supported by a basement membrane. Use of
the bioprinter allowed reproducible generation of spatially-
defined tissues created on standard multi-well Transwell inserts
(Figure 1B, King et al., 2016).
Following culture for 14 days, the PT tissues were analyzed
for tissue organization, cell morphology, and retention of
endothelial and epithelial markers (Figure 2, King et al., 2016).
A hematoxylin and eosin (H&E) stain of the 3D tissues
showed an interstitial layer with low cell density composed
of spindle-shaped fibroblasts and areas of HUVEC undergoing
remodeling to form endothelial cell-lined networks (Figure 2A).
A monolayer of RPTEC cells was observed immediately above
the interstitium, with columnar morphology and basally oriented
nuclei. The interstitial cells themselves secreted abundant ECM
as shown by Gomori’s trichrome stain, with fibrillar structures
visible surrounding the endothelial cell networks in the middle of
the tissue as well as underlying the epithelial layer (Figure 2B).
The putative endothelial cell networks observed by H&E and
trichrome expressed CD31 and demonstrated that the HUVEC
had organized to form open spaces lined by endothelial cells
(Figure 2C). Separating the interstitium from the epithelium was
a collagen IV-rich basement membrane immediately adjacent to
the basal side of the epithelial cells (Figure 2E). The RPTEC cells
in the 3D PT model expressed cytokeratin 18 uniformly across
the monolayer (Figure 2D) with E-cadherin localized laterally
between adjacent cells (Figure 2E). Polarized distribution of
Na+/K+ ATPase to the basolateral membrane of RPTEC was also
observed (Figure 2F).
As a first measure of longevity, tissues were assessed for their
ability to reduce resazurin in an alamarBlue assay or to exhibit
FIGURE 1 | Description of a 3D model of the PT tubulointerstitial
interface printed with the NovoGen Bioprinter® instrument. (A)
Schematic diagram showing a multicellular interstitial layer underlying a
basement membrane that supports an epithelial monolayer. (B) Macroscopic
view of 3D PT tissues positioned on Transwell inserts in a standard 24-well
plate (Corning Costar, Corning, NY).
epithelial-specific GGT activity over 4 weeks in culture. The
total tissue metabolic activity of the 3D PT tissues increased
between day 10 and day 15 and then reached a plateau that
was maintained out to day 30, with low variability from tissue
to tissue as demonstrated by the coefficient of variation (%
CV; Supplemental Figure 1A). The increase could reflect an
increase in metabolic activity or an increase in the overall size
of the tissue. The 3D PT tissues exhibited an increase in GGT
activity from 5 mIU/ml at day 7 to 30 mIU/ml at day 30, while
interstitium controls showed negligible activity (Supplemental
Figure 1B, King et al., 2016). As seen in the metabolic activity
assay, analysis of the % CV in the GGT assay suggested low
tissue-to-tissue variability. Because of an inability to normalize
this readout to total protein content, it is unclear whether the
increase reflects an increase in enzymatic activity, epithelial cell
number or overall tissue size. While the exact mechanisms are
not well understood, the lack of decline in viability and GGT over
time suggests that there is sustained tissue health over the 4 week
timecourse. Together, these findings demonstrate the formation
of a robust 3D model of the renal tubulointerstitial interface
capable of supporting RPTECmorphology, viability and function
for at least 4 weeks.
Characterization of Barrier Function
To measure the barrier function of the 3D PT tissues,
trans-epithelial electrical resistance (TEER) measurements were
performed using an Ussing chamber after 21 days in culture.
Table 3 and King et al. (2016) shows the average area-corrected
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FIGURE 2 | Histological characterization of 3D PT tissues. Representative images of tissues cultured for 14 days are shown. (A) H&E stain showing fully cellular
tissue and organization of interstitial and epithelial layers. (B) Gomori’s trichrome stain showing deposition of collagen throughout the tissue. (C) The interstitial layer
demonstrates extensive endothelial cell-lined networks (red, CD31). (D) RPTEC form a monolayer and express cytokeratin 18 (red). (E) A collagen IV-rich basement
membrane underlies the epithelial cells and E-cadherin localizes to tight junctions between the cells (red, collagen IV; green, E-cadherin). (F) Na+K+ATPase localizes
to the basolateral membrane of RPTEC.
resistance values for 3D PT tissues, which averaged 18.1  ∗cm2.
The apparent permeability (Papp) was also measured in 3D
PT tissues by addition of Lucifer yellow to the apical (A) or
basolateral (B) compartment of the Transwell and detection of
the fluorophore in the opposite compartment as a function of
time. 3D PT tissues exhibited an average A→B Papp value of
6.31 × 10−6 ± 0.83 × 10 cm/s−6 and a B→A Papp value of
5.33 × 10−6 ± 1.06 × 10−6 cm/s, for an eﬄux ratio of 0.84
(Table 3). As the B→A Papp/A→B Papp eﬄux ratio approached
unity, the data shows active transport played a minimal role in
the disposition of Lucifer yellow in the model. Empty Transwells
devoid of tissues exhibited much higher permeability, with an
average A→B Papp value of 308 × 10
−6 ± 3.6 × 10−6 cm/s,
supporting the conclusion that the 3D PT tissues themselves were
responsible for the observed barrier function. When compared
to literature findings, these results demonstrate that the barrier
formed by the RPTEC cells in the 3D PT tissues is leakier than
isolated epithelial monolayers but more characteristic of the
barrier observed for the PT in vivo (Boulpaep and Seely, 1971;
Liang et al., 1999).
Assessment of the Intrarenal
Renin-Angiotensin System (RAS)
To determine whether the 3D PT tissues retained a viable RAS,
gene expression of several members of the pathway were first
measured. Gene expression analysis of the tissues over 30 days in
culture showed detectable levels of ACE, angiotensinogen (AGT),
angiotensin receptor I (AGTR1), and renin (Supplemental Table
1). Consistent with the gene expression data, ACE protein
was detected in both conditioned media and tissue lysates,
with higher detection in the tissue lysates (Figure 3A). This
may correlate with the observed expression of ACE in the
brush border of the PT (Kobori et al., 2007). To evaluate the
function of ACE, 3D PT tissues were dosed with 5 ng/ml
human angiotensin I for 24 h and assessed for the ability to
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TABLE 3 | Measurement of TEER and apparent permeability in 3D PT tissues.
Tissue R(Avg) *cm2 Papp(A→B) cm/s Papp (B→A) cm/s Efflux ratio
3D PT 18.1 ± 1.3 6.31 × 10−6 ± 0.83 × 10−6 5.33 × 10−6 ± 1.06 × 10−6 0.84
Empty well ND 308 × 10−6 ± 3.63 × 10−6 ND N/A
Tissues were cultured for 14–21 days, and TEER was measured using an Ussing chamber. Apparent permeability was measured by directional detection of Lucifer yellow and calculation
of the efflux ratio of B→A:A→B. Data shown is the mean of 6 replicates plus or minus the standard error of the mean. ND, not detected; N/A, not applicable.
convert angiotensin I to angiotensin II. Following stimulation,
angiotensin II was detected in 3D PT tissues at 0.4 pg/ml
(Figure 3B). Thus, the 3D PT tissues exhibited physiologically
relevant features of the in vivo PT, including development
of barrier functions and conversion of angiotensin I to
angiotensin II.
Analysis of Renal Transporters in 3D PT
Tissues
A key feature of the PT that relates to its susceptibility
to nephrotoxicity is the expression and function of renal
transporters, which take up or eﬄux compounds from the
capillaries surrounding the PT or the glomerular filtrate in the
lumen of the tubule. Primary human RPTEC dedifferentiate
rapidly when cultured in 2D, exhibiting varying levels of renal
transporters and a range of cellular morphologies depending
on the time and method of culture (Supplemental Figure 2,
Wieser et al., 2008; Vesey et al., 2009). We hypothesized that
culturing low-passage primary human RPTEC on a relevant renal
interstitium would preserve transporter expression and function.
To validate the use of the 3D PTmodel for transporter-dependent
toxicity studies, tissues were first analyzed for relative expression
levels of key renal transporter genes by qPCR (Supplemental
Table 1). The 3D PT tissues exhibited stable levels of expression
of many important renal transporters, as well as the epithelial ion
channel NHE3 and the sodium phosphate transporter NAPT2C.
As an additional assessment of the expression of key renal
transporters at the protein level, 3D PT tissues were evaluated
by mass spectrometry for detection of peptides corresponding
to P-gp, OAT1, OAT3, and OCT2 (Figure 4). The expression
of renal transporter proteins was compared to that of human
cortical kidney tissue. For each transporter evaluated, the 3D
PT tissues exhibited low variation in levels of expression across
5 independent tissues from 2 separate experiments. For OAT1,
OAT3, and OCT2, detection was evaluated using 2 different
peptides, which showed slight differences in the total peak area
ratio of the protein detected (Figures 4B–D) attributable to the
variation in ionization efficiency of the two different peptides
analyzed by LC-MS/MS. For each transporter evaluated, the
3D PT tissues exhibited peak area values comparable to that
observed for human kidney cortex tissue. Thus, the 3D PT
tissues exhibit physiologically-relevant levels of renal transporter
proteins, enabling continued evaluation of transporter function
in this system.
To assess both uptake and eﬄux transporter function in the
3D PT model, the glucose uptake transporter SGLT2 and the
xenobiotic eﬄux transporter P-gp were selected for functional
analysis (Figures 5, 6 and King et al., 2016). As shown in
Figure 5A, SGLT2 protein expression was detected primarily at
the apical surface of RPTEC on 3D PT tissues. This pattern
matches what is seen in vivo in the human PT (Brenner,
2008). To evaluate SGLT2 transporter function, tissues were
kept in either normal tissue maintenance media or starved of
glucose for 24 h, followed by stimulation of glucose uptake
by insulin in the presence or absence of the SGLT2 transport
inhibitor canagliflozin (Figure 5B). In tissues maintained in
normal tissue media, treatment with insulin induced a 4-fold
increase in intracellular 2-DG, which decreased by 50% upon co-
administration of the SGLT2 inhibitor canagliflozin (Figure 5B,
black and gray bars). This suggests that there is functional SGLT2
transport in the tissues, and that other transport mechanisms are
also contributing to global glucose uptake. When tissues were
starved overnight, insulin induced an 8-fold increase in glucose
uptake, which was significantly reduced by canagliflozin to levels
indistinguishable from the control tissues (Figure 5B, blue bars).
As expected, starvation increased glucose uptake by 3D PT tissues
beyond that observed for tissues cultured in normal media as
the tissues sought to re-establish glucose homeostasis lost during
culture in the absence of glucose, and SGLT2 appears to play a
role in this process.
To assess P-gp mediated eﬄux capabilities in 3D PT tissues,
we first wanted to determine the localization of the transporter
protein. As expected for native proximal tubule, P-gp protein
expression was detected at the apical surface of the RPTEC cells
in the 3D PT model (Figure 6A). To evaluate P-gp function,
3D PT tissues were loaded with rhodamine 123 (R123) in the
presence or absence of zosuquidar, a P-gp inhibitor. Following
uptake, tissues were washed and cryosectioned to detect the
presence of R123 in the RPTEC of the PT model (green).
Tissues treated with buffer alone exhibited no green fluorescence
(control), while tissues treated with R123 exhibited punctate
fluorescent expression in the cytoplasm of the RPTEC. Upon
blocking P-gp-mediated eﬄux with zosuquidar, an increase in
accumulated fluorescence was observed in the epithelium with
the RPTEC monolayer fluorescing uniformly throughout the
cytoplasm (Figure 6B). Image quantification showed that tissues
exposed to R123 exhibited a 4-fold increase over control tissues,
while treatment with R123 plus zosuquidar resulted in a 6-fold
increase in fluorescence over control tissues and a significant
increase compared to R123- treatment alone (Figure 6C). Thus
the 3D PT tissues exhibited stable expression of renal transporters
over time, and functional activity of the endogenous substrate
transporter SGLT2 and the xenobiotic transporter P-gp were
verified.
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FIGURE 3 | RAS pathway component activity in 3D PT tissues. (A) Expression levels of ACE in supernatant and lysates from 3D PT tissues cultured 4 or 14
days. (B) Detection of angiotensin II following ACE-mediated conversion of exogenous angiotensin I. Data shown is the mean of duplicate measurements from 3
independent tissue samples plus or minus the standard error of the mean. ***p < 0.001.
FIGURE 4 | Detection of renal transporter peptides by LC-MS/MS. After 14 days in culture, 3D PT tissues or human kidney cortical tissue were subjected to
tryptic digestion and relative quantitation of renal transporter peptides by mass spectrometry. (A) Detection of P-gp. (B) Detection of OAT1 using 2 different peptides.
(C) Detection of OAT3 using 2 different peptides. (D) Detection of OCT2 using 2 different peptides. Data shown is the mean from 5 independent tissue samples plus
or minus the standard error of the mean.
Assessment of Cisplatin Nephrotoxicity
using 3D PT Tissues
Cisplatin is a chemotherapeutic agent with multiple mechanisms
of action that lead to nephrotoxicity, including generation of
reactive oxygen species and formation of toxic glutathione
conjugates following concentration of the molecule in RPTEC
by renal uptake transporters including OCT2 (Hanigan and
Devarajan, 2003; Yonezawa et al., 2005). In addition, cisplatin
has been reported to lead to tubulointerstitial fibrosis (Guinee
et al., 1993). To assess whether the 3D PT tissues could manifest
OCT2-dependent cisplatin toxicity, tissues were exposed daily
to cisplatin in the presence or absence of the OCT2 inhibitor
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FIGURE 5 | SGLT2 transporter localization and function. (A) After 14 days in culture, 3D PT tissues were stained with antibodies against SGLT2 (green). (B)
Tissues were assessed for retention of the non-metabolizable glucose analog 2-DG in a colorimetric assay in the presence or absence of the glucose uptake inducer
insulin or the SGLT2 inhibitor canalgliflozin (Cana). Starved tissues are indicated by the blue family of bars. Data shown is the mean of triplicate measurements across
6 independent tissue samples plus or minus the standard error of the mean. *p < 0.01 between the groups compared by one-way ANOVA.
FIGURE 6 | P-gp transporter localization and function. (A) After 14 days in culture, 3D PT tissues were stained with antibodies against P-gp (green). (B) Tissues
were exposed to 5 µM zosuquidar alone, 10 µM rhodamine 123, or rhodamine 123 + zosuquidar for 2 h. Tissues were snap fixed, cryosectioned, and all tissues
were imaged at the same exposure time. (C) Fluorescence intensity was quantified in Image J. Data shown represents the mean of duplicate measurements from at
least 6 independent tissue samples plus or minus the standard error of the mean. *p < 0.0001 between the groups as compared by one-way ANOVA.
cimetidine followed by measurement of overall viability, release
of LDH, and histological analysis (Figure 7 and King et al., 2016).
Tissues treated with cisplatin exhibited a significant decrease
in alamarBlue metabolism at doses as low as 1 µM, with
an LD 50 value of 5.72 µM and complete loss of viability
at 10 µM (Figure 7A). No loss of viability was observed in
tissues treated with cimetidine alone compared to the vehicle
control (Figure 7B). While tissues treated with 5 µM cisplatin
exhibited a nearly 50% decrease in viability, tissues treated with
a combination of cisplatin and cimetidine exhibited viability
levels indistinguishable from vehicle or cimetidine-only controls
(Figure 7B). LDH release, indicative of toxicity, peaked at
treatment day 5 in tissues treated with 5 µM cisplatin alone, with
an observed 3-fold increase over vehicle controls (Figure 7C).
Tissues treated with cisplatin plus cimetidine did not exhibit the
same damage response, showing only slightly elevated levels of
LDH release compared to vehicle at day 5 and indistinguishable
levels vs. control-treated tissues by day 7 (Figure 7C).
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FIGURE 7 | Reduction of overall viability in 3D PT tissues in response to cisplatin and rescue by the OCT2 inhibitor cimetidine. Tissues were treated daily
for 7 days with increasing doses of cisplatin (A) or with 5 µM cisplatin (Cis) in the presence or absence of 1mM cimetidine (Cim; B). Cimetidine alone was also tested
as a control (B). Overall tissue viability was measured by alamarBlue metabolism. Data shown is indicative of duplicate measurements from 3 individual tissues.
Asterisks (*) indicate p < 0.0005 compared to vehicle control by one-way ANOVA and Dunnett’s post-test. % CV across multiple 3D PT tissues from separate
experiments at each time point is shown below each graph. (C) Daily LDH release from tissues treated with cimetidine, cisplatin, or a combination of cisplatin and
cimetidine as a measure of toxicity. Data shown represents the mean of duplicate measurements from 3 independent tissue samples plus or minus standard deviation.
Asterisks (*) indicate p < 0.002 between vehicle and treatment groups as assessed by two-way ANOVA. Number sign (#) indicates p < 0.001 between 5 µM cisplatin
and 5 µM cisplatin + 1 mM cimetidine as assessed by two-way ANOVA.
Histological analysis by H&E staining confirmed the loss
of epithelial viability in response to cisplatin (Figure 8, King
et al., 2016). Vehicle or cimetidine-only tissues exhibited healthy,
columnar RPTEC with round nuclei (Figures 8A,B), while
tissues treated with 5 µM cisplatin exhibited a more squamous
morphology and loss of nuclei (Figure 8C). Tissues treated with
cisplatin plus cimetidine exhibited a substantial improvement in
epithelial morphology vs. cisplatin alone, with partial restoration
of nuclear localization and columnar RPTEC (Figure 8D). The
loss of epithelial cells in response to cisplatin and rescue by
cimetidine was further supported by changes in GGT activity
in treated tissues, though changes in enzymatic activity or
overall tissue mass cannot be fully excluded (Supplemental
Figure 3A, King et al., 2016). To evaluate RPTEC proliferation
in response to damage induced by cisplatin, tissues were
stained for proliferating cell nuclear antigen (PCNA). Vehicle or
cimetidine-treated control tissues exhibited low levels of RPTEC
proliferation; however, a dose-dependent proliferative response
was observed in tissues treated with cisplatin (Figure 9). This
increased proliferation in the RPTEC of 3D PT tissues was
decreased by co-administration of cimetidine. Thus, the 3D PT
tissues were able to recapitulate nephrotoxicity after exposure
to clinically-relevant doses of cisplatin and confirm the role
of the OCT2 transporter as a mechanism of nephrotoxicity
induction.
Demonstration of TGFβ-Induced Fibrotic
Effects on the Interstitium of 3D PT Tissues
One key deficit of standard 2D epithelial models is their inability
to detect effects on the renal interstitium, which in turn could go
on to impact global tissue structure and function. To demonstrate
the ability of the 3D PT tissues to respond to agents that impact
cells of the interstitial compartment, the ability of TGFβ to
induce a fibrotic response was assessed. Following treatment of
3D PT tissues daily for 7 days with vehicle or TGFβ, viability
was measured by resazurin reduction and the expression of
genes associated with human renal tubulointerstitial fibrosis was
measured. No significant loss of metabolic activity was detected
in tissues treated with TGFβ compared to tissues treated with
vehicle (Figure 10A). At a dose of 3.3 and 10 ng/ml TGFβ,
a reduction in GGT activity was observed, indicating that the
higher doses may impact the function of epithelial cells or
induce toxicity (Supplemental Figure 3B). TGFβ elicited a dose-
dependent increase in collagen 1 (COL1A1), connective tissue
growth factor (CTGF), fibroblast-activating protein (FAP), and
platelet-derived growth factor receptor β (Figure 10B). The
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FIGURE 8 | Histological analysis of cisplatin toxicity. Representative H&E images are shown for tissues dosed daily for 7 days with vehicle (A), 1 mM cimetidine
(B), 5 µM cisplatin (C), or 5 µM cisplatin + 1 mM cimetidine (D).
FIGURE 9 | Proliferation of RPTEC in response to damage. Tissues were dosed daily for 7 days with vehicle (A), 2.5 µM cisplatin (B), 5 µM cisplatin (C), or 5
µM cisplatin + 1 mM cimetidine (D) and stained with an antibody against PCNA. Proliferating cells are marked with white arrows.
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FIGURE 10 | Response of 3D PT tissues to TGFβ. Tissues were dosed daily for 7 days with vehicle, 0.37 ng/ml TGFβ, 1.1 ng/ml TGFβ, 3.3 ng/ml TGFβ, or 10
ng/ml TGFβ. (A) alamarBlue analysis of overall tissue metabolic activity. Data shown is the average of 3 tissue samples per condition and is represented as the fold
change relative to the vehicle control. No statistically significant differences were detected between treatment groups. (B) Induction of the fibrotic markers collagen I
(COL1A1), connective tissue growth factor (CTGF), fibroblast-activating protein (FAP), or platelet-derived growth factor receptor β (PDGFRB) was assessed by
quantitative RT-PCR. Data shown is the average of 3 tissue samples per condition and is represented as the fold change relative to the vehicle control. *p < 0.0001 for
each condition compared to vehicle. (C) Representative Gomori’s trichrome stains for ECM deposition are shown. (D) Quantification of Sirius red-stained collagen in
tissue sections is shown. Data represents the average of 4 technical replicates per tissue, 3 tissues per condition and is represented as the fold change relative to the
vehicle control following normalization to total protein content as measured by Fast Green staining. *p < 0.05 for each condition compared to vehicle.
fibrotic response of tissues treated with TGFβ was observed
histologically by Gomori’s trichrome stain for ECM deposition,
with TGFβ inducing thickening of the tissue via expansion of
the interstitial layer (Figure 10C). The increased deposition of
ECM seen by histology was quantified by Sirius Red/Fast Green
staining; treatment with TGFβ at 1.1 ng/ml, 3.3 ng/ml, and
10 ng/ml significantly induced collagen levels in 3D PT tissues
(Figure 10D). Together, this data highlights the ability of the
tissues to manifest the effects of test agents on multiple cell types
within the tubule interstitium as well as the epithelium, and may
provide a system to assess the multiple pathways leading to renal
fibrosis.
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DISCUSSION
To date, very few systems have been developed to study the
human renal tubulointerstitial interface in vitro. A variety of
systems for 3D culture of RPTEC in isolation have been
developed, including culturing cells in Matrigel, culturing cells
as organoids on a variety of scaffolds such as hyaluronic acid or
silk, and culture of RPTEC in microfluidic devices (“kidney on a
chip”) (Joraku et al., 2009; Subramanian et al., 2010; Astashkina
et al., 2012; Jang et al., 2013). However, these systems lack
direct contact between the epithelium and relevant interstitial cell
types, including fibroblasts and endothelial cells, that play both a
structural role in orienting the epithelium as well as providing
a source of growth factors critical for the continued health and
organization of the epithelium (Lemley and Kriz, 1991; Kaissling
and Le Hir, 2008; Meran and Steadman, 2011). Without these
supportive cell types, RPTEC rapidly lose their native phenotype
in culture, thus preventing the ability to perform the chronic,
low dose exposure studies necessary to predict how a molecule
will perform in the clinic. In addition, the lack of supporting
interstitial cell types in other culture systems precludes the ability
to model drug-induced and disease relevant states that require an
interaction between the epithelium and interstitium, like fibrosis.
One goal of this study was to use 3D bioprinting to build
and characterize a model in which a renal interstitium supported
the continued growth and maintenance of healthy epithelia. The
renal fibroblasts and endothelial cells provided a robust source
of endogenously-produced extracellular matrix, which enabled
tissue formation without the use of exogenous scaffolding as well
as supported the formation of open networks of endothelial cells
in the interstitial layer and a collagen-rich basement membrane
underlying the epithelium. The endothelial networks form open
spaces in the interstitium that may allow better access of media
and nutrients to the entirety of the tissue. While the interstitial
layer is thicker than the native human renal interstitium, the
combination of the renal fibroblasts with the endothelial cells
does enable a cellular density more reminiscent of the in vivo
tissue, which contains fibroblast-like cells immediately adjacent
to the epithelium (Lemley and Kriz, 1991).
3D PT tissues were evaluated for their ability to recapitulate
physiologically-relevant aspects of the in vivo proximal tubule,
including reconstitution of the intrarenal RAS and barrier
functions. The human PT expresses ACE at the apical surface
of RPTEC in order to convert angiotensin I to angiotensin II
(Schulz et al., 1988; Ichihara et al., 2004), which then plays
a critical role in regulating sodium transport to influence
hypertension through feedback onto the renal microvasculature
and glomerulus (Kobori et al., 2007). The 3D PT model was
able to demonstrate angiotensin II conversion in response
to angiotensin I stimulation (Figure 3B). Future experiments
exploring the RAS in the 3D PT model could potentially be
used to separate the effects of new therapeutics for hypertension
on the glomerulus vs. the PT, particularly with regard to
mitigating nephrotoxicity as a result of hypertension. Another
important function of the PT is to serve as an epithelial barrier
controlling the movement of specific types of molecules across
the monolayer. The PT is the primary site of re-uptake of water
and solutes following glomerular filtration, and as such, must
form a more permeable barrier than that observed more distally
in the nephron (Ussing et al., 1974; Greger, 1996). Monolayer
cultures of renal epithelia such as HK-2 and primary RPTEC
cells have been shown to exhibit high TEER values of 100–1,000
∗cm2, with a high degree of variability in those values attributed
to differences in culture methods and variations between human
kidney donors (Prozialeck et al., 2006). In contrast, in vivo
tubules exhibit values between 6.6 and 11.6 ∗cm2 (Boulpaep
and Seely, 1971; Liang et al., 1999). In this study, 3D PT tissues
exhibited TEER values of 18.1 ∗cm2 (Table 3), which more
closely matches values measured in vivo. Monolayer epithelial
cultures with tight barrier function and high TEER values (>100
∗cm2) exhibit a Papp of 0.5- 1 × 10
−6 cm/s for Lucifer yellow
(Tran et al., 2004). The average Papp value for Lucifer yellow in
3D PT tissues was 6.31 × 10−6 cm/s for A→B and 5.33 × 10−6
cm/s for B→A, indicating transcellular or paracellular transport
through the tissues and confirming the leaky barrier function
noted by TEER measurements (Table 3). One possible cause for
this is the presence of the extracellular matrix-rich interstitium
underlying the RPTEC, which may support the formation of
a leaky barrier through formation of a physiologically-relevant
basement membrane structure. It will be important to evaluate
additional substrates for apparent permeability in this system, as
previous reports in rat and killifish culture systems have indicated
that Lucifer yellow may undergo active transport in the proximal
tubules of these non-human species (Masereeuw et al., 1999).
Primary human RPTEC provide the advantage of expressing
a variety of transporters known to play a role in drug-induced
kidney injury; however, these cells can be cultured for a limited
time (<14 days) before undergoing senescence or epithelial
to mesenchymal transition and concomitant loss of renal
transporter expression and function (Supplemental Figure 2). In
contrast, culturing these cells in a 3D context on an interstitial
layer enabled retention of epithelial cell viability and function
for at least 30 days in culture while retaining gene expression
of many renal transporters such as cubilin and megalin, MATE1
and MATE2K, OCT2, BCRP, and P-gp (Supplemental Table 1).
Of particular note, the key xenobiotic transporters OAT1 and
OAT3 exhibited low or non-detectable levels of mRNA in all the
donors tested. In the liver, a discrepancy between mRNA and
protein levels has been characterized for hepatic transporters,
withmost transporters evaluated showing no correlation between
mRNA expression by qPCR and protein expression detected my
LC-MS/MS (Ohtsuki et al., 2012). Following detection of low
amounts of OAT1 andOAT3mRNA, we evaluated the expression
of P-gp, OCT2, OAT1, and OAT3 by LC-MS/MS. For the 4
transporters evaluated, 3D PT tissues exhibited comparable levels
of expression to that observed for normal human kidney cortical
tissue (Figure 4). While this method enabled comparison of 3D
PT tissues and human kidney for each transporter, absolute
quantitative values were not able to be determined, which
may also influence transporter functional activity. To confirm
functional transport, the activity of the xenobiotic transporter P-
gp and endogenous substrate transporter SGLT2 were confirmed
in 3D PT tissues by transport of R123 and a glucose analog,
respectively (Figures 5, 6). LC-MS/MS detection of SGLT2 was
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hampered by a lack of optimized detection methods, but stable
SGLT2 expression was detected by qPCR (Supplemental Table 1),
correlating with the functional activity observed. Rhodamine 123
has previously been used to demonstrate P-gp function in HK-
2 cells (Tramonti et al., 2009); however, in isolated rat kidneys,
additional renal transporters such as OCT1 and OCT2 were
involved in rhodamine 123 transport (Heemskerk et al., 2008).
Future studies will investigate the function of renal transporters
by assessing the directional transport of small molecules coupled
with detection by LC-MS/MS, using specific substrates and
inhibitors. The ability to do this in a native expression systemmay
enable more accurate prediction of active transport potential,
decreasing the reliance on artificial overexpression models.
Sustained expression and function of renal transporters in the 3D
PT tissues may also enable the elucidation of complex molecular
mechanisms of action of human nephrotoxins following chronic
exposure.
A human 3D multi-cellular renal tissue composed of distinct
epithelial and interstitial cell compartments provides a unique
test platform for evaluating new drug entities for potential
nephrotoxicity, allowing for the assessment of biochemical,
transcriptional, and histological endpoints across multiple cell
types and anatomical locations ex vivo. To provide initial proof-
of-concept data that this model may be used for nephrotoxicity
testing, 3D PT tissues were exposed to the classical nephrotoxin
cisplatin. 3D PT tissues exhibited an LD50 value of 5.72
µM (Figure 7A), consistent with previously reported values
for in vitro and ex vivo cisplatin toxicity (Tay et al., 1988;
Katsuda et al., 2010). In addition, cisplatin treatment led to a
loss of epithelial cells in the tissue, as assessed by histology.
While several mechanisms likely play a role in cisplatin-
mediated nephrotoxicity, including generation of reactive oxygen
species and creation of toxic intermediates through glutathione
conjugation, these mechanisms occur after cisplatin has been
taken up by RPTECs (Hanigan and Devarajan, 2003). This
uptake is thought to occur primarily through the action
of the OCT2 renal transporter, although other transporters
such as the copper transporters (CTR1 and 2) may play a
role as well (Ciarimboli et al., 2005). In the current study,
inhibition of the OCT2 transporter by cimetidine successfully
protected against cisplatin-induced loss of viability and epithelial
function (Figures 7–9). This mechanism is clinically relevant,
as polymorphisms in OCT2 that influence its function are
predictive of cisplatin-induced AKI, and animal models that
lack OCT2 expression exhibit decreased sensitivity to cisplatin
(Ciarimboli et al., 2005, 2010). In response to apoptosis and
loss of PT epithelial cells during AKI, the PT epithelium has
demonstrated a high capacity for compensatory proliferation
and repopulation in vivo (Fujigaki, 2012). Analogously, we
observed a dose-dependent increase in proliferating RPTEC
in 3D PT tissues exposed to cisplatin, which was reduced in
tissues treated with cimetidine (Figure 9). In humans, cimetidine
therapy or the presence of loss-of-function mutations in OCT2
correlated with decreased urinary cystatin C following cisplatin
administration, demonstrating the possible utility of this therapy
as an ameliorative during chemotherapy (Zhang and Zhou,
2012).
Following validation of basic PT-relevant characteristics and
the ability to respond to the nephrotoxin cisplatin, we next
sought to demonstrate a feature of this novel model that
could not be demonstrated by traditional epithelial monolayer
cultures. To demonstrate aspects of tubulointerstitial fibrosis
that required interaction between the PT epithelial cells and
the interstitial cells of the model, we treated 3D tissues
with TGFβ, a peptide growth factor required for many
aspects of cellular homeostasis including intracellular signaling,
proliferation, apoptosis, and ECM deposition. In the kidney,
TGFβ signaling, often downstream of kidney injury, plays a role
in induction of a fibrotic response, characterized by epithelial to
mesenchymal transition, expansion of myofibroblasts, increased
immune infiltration, and excessive ECM deposition (Meran and
Steadman, 2011; Moll et al., 2013). Following treatment of 3D
PT tissues with TGFβ for 7 days, we observed an increase in
fibrosis-related genes as well as a dramatic increase in tissue
thickness and ECM deposition as demonstrated histologically
(Figure 10). The increase in expression of COL1A1, CTGF, FAP,
and PDGFRB have been previously shown to correlate with
human tubulointerstitial fibrosis (Henger et al., 2004; Meran
and Steadman, 2011; Nogare et al., 2013; Ostendorf et al.,
2014) and were confirmed in this system. Loss of GGT activity
was observed at the highest dose of TGFβ tested (10 ng/ml)
(Supplemental Figure 3C) without an overt loss of metabolic
activity (Figure 10A). One possibility is that the PT cells of
the 3D PT tissues are undergoing a TGFβ-induced epithelial-
to-mesenchymal transition, although this hypothesis remains to
be validated. Future experiments will be directed at evaluating
drug-induced renal fibrosis using this system, with the goal of
developing novel anti-fibrotic drugs to ameliorate this condition,
which can lead to loss of kidney function.
In summary, we have designed and validated a new in vitro
human 3D tissue model capable of preserving RPTEC function
over an extended time in culture and enabling quantitative
detection of PT nephrotoxicity occurring by specific mechanisms
in multiple cell types. These data suggest that 3D PT tissues
could positively impact the pre-clinical drug discovery pipeline,
helping to prevent costly failures in late stage clinical trials. The
inclusion of a tubulointerstitial interface in the model allows
for exploration of complex, multifactorial disease processes like
fibrosis, as well as assessing the capacity of the RPTEC to
compensate, repopulate and/or regenerate during or after drug-
induced injury. The importance of developing more complex,
multicellular in vitro kidney models has also led to the
development of stem-cell derived organoids containing multiple
regions of the nephron (Takasato et al., 2014, 2015, 2016).
While these models display increased architectural and cellular
complexity, the differentiated cells retain a more immature fetal
phenotype that may limit their utility in toxicology screening
(Takasato et al., 2015). In addition, transport studies are difficult
to perform in self-organizing organoids due to the restricted
access to the tubule lumen. While the region of focus is more
limited, the ability to incorporate primary adult epithelial and
interstitial cells in the 3D PT model in an architecture that allows
access to both the luminal and basolateral surfaces overcomes
some of the challenges of renal organoids. Use of primary
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human RPTECs from multiple donors, including those from
patients with acute or chronic kidney disease, may enable better
understanding of how drugs may perform clinically across a
specific patient population. Additional studies across a panel of
nephrotoxic compounds with differingmechanisms of action will
help to further elucidate the value of the system for screening new
chemical entities. In addition, a single donor of PT epithelial cells
was evaluated in this study to provide initial proof-of-concept.
Future studies will evaluate the performance of cells isolated from
multiple donors, which is critical to fully validate the model. It
is also worth noting that the current system is a static culture,
which is quite different from the laminar flow that a proximal
tubule lumen experiences in vivo. The inclusion of laminar flow
across the RPTEC could further enhance tubular epithelial cell
function; future work will focus on designing a culture apparatus
that allows for the inclusion of laminar flow across the apical
surface. The system may also enable the parallel investigation of
biomarkers that may be useful in noninvasively detecting early
kidney injury.
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